Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan + hydrochlorothiazide in severe essential hypertension
2009-011776-30Phase 4Completed
- Sponsor
- Takeda
- Start
- Jul 2009
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of candesartan and hydrochlorothiazide in essential hypertension (3 arms), sponsored by Takeda. Primary endpoints: Primary: Change in systolic blood pressure from visit 1 to visit 5 and Primary: Change in diastolic blood pressure from visit 1 to visit 5. Started Jul 2009; status: completed.
02
Drugs
candesartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2009-011776-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011776-30.